<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414555</url>
  </required_header>
  <id_info>
    <org_study_id>v1.104112014</org_study_id>
    <nct_id>NCT02414555</nct_id>
  </id_info>
  <brief_title>Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support</brief_title>
  <acronym>KATECHOL</acronym>
  <official_title>Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support, a Randomized Controlled Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Intraoperative hypotension is a common problem that significantly contributes to&#xD;
      perioperative mortality and morbidity. At the moment the &quot;gold standard&quot; for perioperative&#xD;
      fluid management is the so called &quot;goal-directed therapy&quot; that features fluid resuscitation&#xD;
      followed if necessary catecholamines if needed for perioperative cardiocirculatory support.&#xD;
&#xD;
      Worldwide the so called &quot;physiological&quot; sodium chlorid (0.9% NaCl) solution is the most often&#xD;
      used infusate for perioperative fluid management. Despite its widespread use physiological&#xD;
      saline has its major disadvantages such as the increased incidence of metabolic acidosis.&#xD;
      Nevertheless catecholamines have their significant side effects as well (eg diminished renal&#xD;
      perfusion, increased cardiovascular morbidity) and they therefore should be used with&#xD;
      caution.&#xD;
&#xD;
      In a prior study by group members on patients undergoing renal transplantation receiving&#xD;
      either physiological saline or an acetate-buffered infusate showed a 50% decrease in&#xD;
      catecholamine necessity in the acetate-buffered infusate group. The investigators therefore&#xD;
      would like to evaluate the effects of the perioperative fluid choice on the necessity of&#xD;
      catecholamine use.&#xD;
&#xD;
      Aim&#xD;
&#xD;
        -  Evaluation of the perioperative fluid choice on the necessity of catecholamines for&#xD;
           cardiocirculatory support.&#xD;
&#xD;
        -  Description of the relationship between perioperative fluid choice and minimal blood&#xD;
           pressure as well as the time to catecholamine use and their dosage.&#xD;
&#xD;
      Methods The investigators plan a prospective randomized-controlled trial of all patients&#xD;
      undergoing major abdominal surgery at the Vienna General Hospital and Medical University of&#xD;
      Vienna. Fluid management and catecholamine use will be based on a oesophageal Doppler -based&#xD;
      treatment scheme.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient Safety&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catecholamine use to maintain target mean arterial pressure</measure>
    <time_frame>hours of anesthesia (max 10 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference in dose of catecholamines to maintain cardiovascular stability</measure>
    <time_frame>hours of anesthesia (max 10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference in volume to maintain cardiovascular stability</measure>
    <time_frame>hours of anesthesia (max 10 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unplanned ICU transfers</measure>
    <time_frame>hours of anesthesia (max 10 hours)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>NaCl 0.9% BBraun (normale saline)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>154mmol/l sodium, 154mmol/l chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elo-Mel Isoton (balanced acetat-based infusate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasopressor</intervention_name>
    <description>Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor</description>
    <arm_group_label>Elo-Mel Isoton (balanced acetat-based infusate)</arm_group_label>
    <arm_group_label>NaCl 0.9% BBraun (normale saline)</arm_group_label>
    <other_name>phenylephrine, norepinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluid bolus</intervention_name>
    <arm_group_label>Elo-Mel Isoton (balanced acetat-based infusate)</arm_group_label>
    <arm_group_label>NaCl 0.9% BBraun (normale saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>oesophagus doppler (CardioQ)</intervention_name>
    <arm_group_label>Elo-Mel Isoton (balanced acetat-based infusate)</arm_group_label>
    <arm_group_label>NaCl 0.9% BBraun (normale saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>NaCl 0.9% BBraun (normale saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>arterial cannulation</intervention_name>
    <arm_group_label>Elo-Mel Isoton (balanced acetat-based infusate)</arm_group_label>
    <arm_group_label>NaCl 0.9% BBraun (normale saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intravenous peripheral line insertion (17 gauge)</intervention_name>
    <description>for fluid bolus administration</description>
    <arm_group_label>Elo-Mel Isoton (balanced acetat-based infusate)</arm_group_label>
    <arm_group_label>NaCl 0.9% BBraun (normale saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elo-Mel Isoton (balanced acetat-based infusate)</intervention_name>
    <arm_group_label>Elo-Mel Isoton (balanced acetat-based infusate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients scheduled for open elective major abdominal surgery and expected to last&#xD;
             a minimum of 2 hours will be included in the study.&#xD;
&#xD;
        (Major abdominal surgery includes all gynecological, urological and general surgical&#xD;
        operations requiring laparotomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years of age&#xD;
&#xD;
          -  Patients unable to give informed consent&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Patients transferred form the intensive care unit to the operating theater&#xD;
&#xD;
          -  Patients with an already established catecholamine therapy&#xD;
&#xD;
          -  Emergency operation&#xD;
&#xD;
          -  Chronic inflammatory diseases (chronic inflammatory rheumatoid diseases, chronic&#xD;
             inflammatory renal diseases, chronic inflammatory infectious diseases, chronic&#xD;
             inflammatory bowel diseases, chronic liver disease with signs of liver insufficiency)&#xD;
&#xD;
          -  Severe cardiovascular disease (heart disease with an ejection fraction below 30%,&#xD;
             instable coronary syndromes, severe valvular disease)&#xD;
&#xD;
          -  Any signs of infection or sepsis&#xD;
&#xD;
          -  Any contraindication for oesophageal Doppler monitoring (oesophageal and aortic&#xD;
             pathology, planned oesophageal resection)&#xD;
&#xD;
          -  Renal insufficiency with a glomerular filtration rate below 30ml/min&#xD;
&#xD;
          -  Patients with additional epidural anesthesia are excluded from the study if epidural&#xD;
             anesthesia is planned to be used for analgesia intraoperatively&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Markstaller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinic for General Anesthesia, Intensive Care and Pain Management, Medical University of Vienna, Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of General Anesthesiology, Intensive Care and Pain Management, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Pfortmueller Carmen Andrea</investigator_full_name>
    <investigator_title>Department of Anesthesiology, Intensive Care and Pain Management</investigator_title>
  </responsible_party>
  <keyword>Fluid Management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

